EcoDrugPlus

Cholecystokinin B Receptor

Ensembl ID : ENSCSEG00000011297
Gene Symbol: CCKBR
3 Cross references
195 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSCSEG00000005266
Gene Symbol: LOC103389540
3 Cross references
198 Possible Orthologues:

Cholesterol 24-Hydroxylase

Ensembl ID : ENSCSEG00000018705
Gene Symbol: LOC103380705
3 Cross references
259 Possible Orthologues:

Cholesteryl Ester Transfer Protein, Plasma

Ensembl ID : ENSCSEG00000000479
Gene Symbol: CETP
1 Cross references
151 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSCSEG00000004979
Gene Symbol: CHRM3
1 Cross references
188 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSCSEG00000005105
Gene Symbol: CHRM4
3 Cross references
186 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSCSEG00000012549
Gene Symbol: CHRNA3
1 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSCSEG00000002067
Gene Symbol: CHRNB2
3 Cross references
198 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSCSEG00000012528
Gene Symbol: CHRNB4
3 Cross references
194 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSCSEG00000007434
Gene Symbol: CHRM2A
1 Cross references
196 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSCSEG00000003704
Gene Symbol: CHRM5B
1 Cross references
190 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSCSEG00000012046
Gene Symbol: F2R
1 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).